| Bioactivity | ETTAC-2 is a LRG1 PROTAC degrader. ETTAC-2 promotes ubiquitination and degradation of LRG1 (DC50 of 8.38 µM). ETTAC-2 inhibits the TGF-β-Smad3 signaling pathway and diminishes the secretion of fibrosis-associated proteins. ETTAC-2 attenuates the progression of renal fibrosis[1]. |
| Sequence | Lenalidomide-(CC)-Gly-Gly-Glu-Ser-Tyr-Ser-Ala-Lys-His-Arg-Ile-Met-Leu-Thr |
| Shortening | Lenalidomide-(CC)-GGESYSAKHRIMLT |
| Formula | C83H123N23O26S |
| Molar Mass | 1891.07 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Fan L, et al. Targeted degradation of LRG1 to attenuate renal fibrosis. Asian J Pharm Sci. 2024 Aug;19(4):100941. |